Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $6.5 to $10.
Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $6.5 to $10.